BioClonetics Immunotherapeutics, with a valuation of $10 million, is raising funds on Wefunder. The company is developing the first cure for HIV through the use of monoclonal antibodies. BioClonetics Immunotherapeutics has created a cell line that produces an anti-HIV antibody called Clone 3 that neutralizes all clades and groups of HIV isolates. The company is working with world-class laboratories and expects to complete animal trials within 18 to 24 months. Dr. Joseph Cotropia founded BioClonetics Immunotherapeutics in December 2009. The current crowdfunding campaign has a minimum target of $200,000 and a maximum target of $1 million. The campaign proceeds will be used for the production of the recombinant Clone 3 antibody, testing of the recombinant antibody against HIV isolates, initiation of animal trials, and completion of animal trials.